BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 30707228)

  • 1. Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease: A Systematic Review and Meta-analysis.
    Artusi CA; Dwivedi AK; Romagnolo A; Pal G; Kauffman M; Mata I; Patel D; Vizcarra JA; Duker A; Marsili L; Cheeran B; Woo D; Contarino MF; Verhagen L; Lopiano L; Espay AJ; Fasano A; Merola A
    JAMA Netw Open; 2019 Feb; 2(2):e187800. PubMed ID: 30707228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease.
    Liu Y; Li W; Tan C; Liu X; Wang X; Gui Y; Qin L; Deng F; Hu C; Chen L
    J Neurosurg; 2014 Sep; 121(3):709-18. PubMed ID: 24905564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease.
    Chen T; Mirzadeh Z; Chapple KM; Lambert M; Shill HA; Moguel-Cobos G; Tröster AI; Dhall R; Ponce FA
    J Neurosurg; 2018 Mar; 130(1):109-120. PubMed ID: 29547091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations.
    Mangone G; Bekadar S; Cormier-Dequaire F; Tahiri K; Welaratne A; Czernecki V; Pineau F; Karachi C; Castrioto A; Durif F; Tranchant C; Devos D; Thobois S; Meissner WG; Navarro MS; Cornu P; Lesage S; Brice A; Welter ML; Corvol JC;
    Parkinsonism Relat Disord; 2020 Jul; 76():56-62. PubMed ID: 32866938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of deep brain stimulation of the subthalamic nucleus (STN-DBS) in patients with monogenic PRKN and LRRK2 forms of Parkinson's disease.
    Prendes Fernández P; Blázquez Estrada M; Sol Álvarez J; Álvarez Martínez V; Suárez San Martín E; García Fernández C; Álvarez Carriles JC; Lozano Aragoneses B; Saiz Ayala A; Santamarta Liébana E; González Álvarez L
    Parkinsonism Relat Disord; 2023 Feb; 107():105282. PubMed ID: 36657280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep brain stimulation of the subthalamic nucleus for advanced Parkinson disease using general anesthesia: long-term results.
    Harries AM; Kausar J; Roberts SA; Mocroft AP; Hodson JA; Pall HS; Mitchell RD
    J Neurosurg; 2012 Jan; 116(1):107-13. PubMed ID: 21999316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effectiveness of subthalamic deep brain stimulation in Parkinson's disease: A comparative cohort study at 1 year and 5 years.
    Jiang JL; Chen SY; Hsieh TC; Lee CW; Lin SH; Tsai ST
    J Formos Med Assoc; 2015 Sep; 114(9):835-41. PubMed ID: 24103710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation sites in the subthalamic nucleus and clinical improvement in Parkinson's disease: a new approach for active contact localization.
    Garcia-Garcia D; Guridi J; Toledo JB; Alegre M; Obeso JA; Rodríguez-Oroz MC
    J Neurosurg; 2016 Nov; 125(5):1068-1079. PubMed ID: 26848922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects.
    Vizcarra JA; Situ-Kcomt M; Artusi CA; Duker AP; Lopiano L; Okun MS; Espay AJ; Merola A
    J Neurol; 2019 Feb; 266(2):289-297. PubMed ID: 29909467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease.
    Greenbaum L; Israeli-Korn SD; Cohen OS; Elincx-Benizri S; Yahalom G; Kozlova E; Strauss H; Molshatzki N; Inzelberg R; Spiegelmann R; Israel Z; Hassin-Baer S
    Parkinsonism Relat Disord; 2013 Nov; 19(11):1053-6. PubMed ID: 23932063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
    Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
    J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation.
    Castrioto A; Lozano AM; Poon YY; Lang AE; Fallis M; Moro E
    Arch Neurol; 2011 Dec; 68(12):1550-6. PubMed ID: 21825213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of bilateral subthalamic stimulation on alexithymia in Parkinson's disease.
    Dafsari HS; Ray-Chaudhuri K; Mahlstedt P; Sachse L; Steffen JK; Petry-Schmelzer JN; Dembek TA; Reker P; Barbe MT; Visser-Vandewalle V; Fink GR; Timmermann L
    Eur J Neurol; 2019 Feb; 26(2):222-e17. PubMed ID: 30107062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacies of globus pallidus stimulation and subthalamic nucleus stimulation for advanced Parkinson's disease: a meta-analysis of randomized controlled trials.
    Tan ZG; Zhou Q; Huang T; Jiang Y
    Clin Interv Aging; 2016; 11():777-86. PubMed ID: 27382262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subthalamic nucleus and globus pallidus internus stimulation for the treatment of Parkinson's disease: A systematic review.
    Xu H; Zheng F; Krischek B; Ding W; Xiong C; Wang X; Niu C
    J Int Med Res; 2017 Oct; 45(5):1602-1612. PubMed ID: 28701061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers.
    Sayad M; Zouambia M; Chaouch M; Ferrat F; Nebbal M; Bendini M; Lesage S; Brice A; Brahim Errahmani M; Asselah B
    BMC Neurosci; 2016 Feb; 17():6. PubMed ID: 26831335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
    Dafsari HS; Martinez-Martin P; Rizos A; Trost M; Dos Santos Ghilardi MG; Reddy P; Sauerbier A; Petry-Schmelzer JN; Kramberger M; Borgemeester RWK; Barbe MT; Ashkan K; Silverdale M; Evans J; Odin P; Fonoff ET; Fink GR; Henriksen T; Ebersbach G; Pirtošek Z; Visser-Vandewalle V; Antonini A; Timmermann L; Ray Chaudhuri K;
    Mov Disord; 2019 Mar; 34(3):353-365. PubMed ID: 30719763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of elderly and young patient populations treated with deep brain stimulation for Parkinson's disease: long-term outcomes with up to 7 years of follow-up.
    Hanna JA; Scullen T; Kahn L; Mathkour M; Gouveia EE; Garces J; Evans LM; Lea G; Houghton DJ; Biro E; Bui CJ; Sulaiman OA; Smith RD
    J Neurosurg; 2018 Sep; 131(3):807-812. PubMed ID: 30265192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes.
    Kleiner-Fisman G; Herzog J; Fisman DN; Tamma F; Lyons KE; Pahwa R; Lang AE; Deuschl G
    Mov Disord; 2006 Jun; 21 Suppl 14():S290-304. PubMed ID: 16892449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.